Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 20Squamous Cell Carcinoma of Head and Neck 19Esophageal Neoplasms 19Head and Neck Neoplasms 13Nasopharyngeal Carcinoma 12Uterine Cervical Neoplasms 10Pancreatic Neoplasms 9Oropharyngeal Neoplasms 8Lung Neoplasms 7Glioblastoma 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Squamous Cell 6Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Colorectal Neoplasms 4Carcinoma 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Laryngeal Neoplasms 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms by Site 2Nasopharyngeal Neoplasms 2NSCLC 2

Interventions

trilaciclib 1Observation 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelosuppression × Chemoradiotherapy × Clear all
NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡